Lenalidomide naïve Follicular Lymphoma
Showing 1 - 25 of 7,589
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lenalidomide combined with G-CHOP (LO CHOP)
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Obinutuzumab in Combination With Lenalidomide in Relapsed or
Recruiting
- Follicular Lymphoma
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital ,Chinese Aca
Apr 27, 2023
Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)
Not yet recruiting
- Follicular Lymphoma
- lenalidomide
- +2 more
-
Shanghai, Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023
Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)
Not yet recruiting
- Follicular Lymphoma
- Biospecimen Collection
- +7 more
-
Duarte, California
- +1 more
Oct 27, 2023
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
- Zanubrutinib
- +3 more
-
Westbury, New YorkClinical Research Alliance, Inc.
Nov 14, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Obinutuzumab-based Therapy for Previously Untreated FL
Recruiting
- Follicular Lymphoma
- Obinutuzumab
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 3, 2023
Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)
Terminated
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
-
Fort Myers, Florida
- +2 more
Jul 20, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,
Recruiting
- Follicular Lymphoma and Marginal Zone Lymphoma
- Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
- lenalinomide
-
Beijing, ChinaChinese Academy of Medical Sciences and Peking Union Medical Col
Feb 13, 2022
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1
Active, not recruiting
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- +12 more
- Lenalidomide
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,
Recruiting
- Follicular Lymphoma
- +2 more
-
New Haven, Connecticut
- +2 more
Jul 14, 2022
Follicular Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Tocilizumab, Lenalidomide)
Recruiting
- Follicular Lymphoma
- Mosunetuzumab (IV)
- +3 more
-
Duarte, California
- +21 more
Jan 10, 2023
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Axicabtagene Ciloleucel
- +8 more
-
Denver, Colorado
- +6 more
Dec 2, 2022